Regenxbio
RGNX
165 hedge funds and large institutions have $896M invested in Regenxbio in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 61 increasing their positions, 56 reducing their positions, and 37 closing their positions.
36% more call options, than puts
Call options by funds: $3.42M | Put options by funds: $2.51M
2.63% more ownership
Funds ownership: 81.26% → 83.9% (+2.6%)
9% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 56
12% less funds holding
Funds holding: 188 → 165 (-23)
23% less capital invested
Capital invested by funds: $1.16B → $896M (-$262M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
54% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$9.52M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$7.45M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$7.44M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$7.18M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$4.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$12M |
| 2 |
Millennium Management
New York
|
-$7.25M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.91M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.4M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$2.99M |
RGNX Hedge Fund Activity: Q2 2022 in Review
165 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q2 2022, worth a combined $896M — down 23% from $1.16B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of RGNX and 17 opened new positions — a net loss of 20 holders — while 56 trimmed existing stakes and 61 added.
The largest buyer was Goldman Sachs, adding an estimated $9.52M. The largest seller was JP Morgan Chase, cutting an estimated $12M.
- 165 institutional investors held Regenxbio (RGNX) as of Q2 2022, down from 188 in Q1 2022.
- Funds reported $896M of Regenxbio stock for Q2 2022, down 23% quarter-over-quarter.
- 17 funds opened new Regenxbio positions in Q2 2022 and 37 closed out, a net change of -20 holders.
- The largest Regenxbio buyer in Q2 2022 was Goldman Sachs, an estimated $9.52M added.
- The largest Regenxbio seller in Q2 2022 was JP Morgan Chase, an estimated $12M sold.
Based on aggregated 13F filings for Q2 2022.